1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Antibiotics, medicinal plants, superbugs and the coming antimicrobial resistant drugs pandemic : global markets, competitors and opportuninites - 2014 - 2019 Analysis and Forecasts

Antibiotics, medicinal plants, superbugs and the coming antimicrobial resistant drugs pandemic : global markets, competitors and opportuninites - 2014 - 2019 Analysis and Forecasts

  • May 2014
  • 373 pages
  • ID: 2116087

Summary

Table of Contents

Search Inside

An Antibiotic is an agent that either kills or inhibits the growth of a microorganism. The world is now facing a grave situation: it is losing the battle against infectious diseases; bacteria are fighting back and are becoming resistant to modern medicine; in short, pharmaceutical drugs don’t work. If resistance is allowed to increase, in a few decades people may start dying from the most commonplace of ailments that today can be treated easily. In fact, the ability of organisms to develop resistance to the effects of antimicrobial therapies developed to kill them is potentially the greatest challenge to healthcare in the 21st century.

Antimicrobial resistance (AMR) is a form of drug resistance whereby some sub-populations of a microorganism, usually a bacterial species, are able to survive after exposure to one or more antibiotics. Pathogens resistant to multiple antibiotics are considered multidrug resistant (MDR) or, more colloquially, superbugs.

The US and world are in the beginning of an emerging crisis of Antibiotic resistance for microbial pathogens. Epidemic antibiotic resistance has been described in numerous pathogens in varying contexts, including, but not limited to: MRSA (methicillin-resistant Staphylococcus aureus), common respiratory pathogens, including Streptococcus pneumoniae and Mycobacterium tuberculosis, and epidemic increases in multidrug-resistant and, increasingly, truly pan-resistant, gram-negative bacilli.

Why is the level of concern increasing now? It is because the increase in organisms resistant to multiple therapies is now coinciding with the reduction in new therapies coming to market to replace ineffective ones.

Herbal medicine, including medicinal plants, was the only way people could treat infectious diseases until the early 20th century. Since then, pharmaceutical drugs have become the main method for treating bacterial infections. However, the pharmaceutical drug pipeline is almost dry. At the same time, growing consumer awareness of the benefits of herbal medicine, along with a backlash against the exorbitant prices and dangerous side effects of pharmaceutical drugs, have led to a renaissance in the use of medicinal plants. Consumers are starting to focus on keeping healthy rather than dealing with acute situations that require the use of expensive pharmaceutical drugs. Medicinal plants fit perfectly into this new paradigm. And for this reason, their use is forecast to grow dramatically.

This report looks at the use of medicinal plants, rather than Antibiotics, to both treat and prevent bacterial infections.

Specifically, it provides:

• A detailed look at Antibiotics and Antimicrobial Resistant drugs.
• Analysis of the Antibiotics market.
• In-depth examination of Antibacterial Medicinal Plants.
• Analysis of the Medicinal Plants market.

Additionally, profiles of 127 private and public companies involved in the Antibiotics and Medicinal Plants industries as producers, distributors, and retailers are given. The report also includes 32 tables and 32 figures.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Nicolas helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Global Companion Animal Specialty Drugs Market 2017-2021

Companion Animal Specialty Drugs Sector: Worldwide Forecast until 2021

  • $ 3500
  • Industry report
  • November 2017
  • by Infiniti Research Limited

About Companion Animal Specialty DrugsCompanion animals are becoming a part of urban population. The factors that have contributed to increased companion animal ownership includes nuclear families and ...

Keratitis Global Clinical Trials Review, H2, 2017

Clinical Research in Keratitis in H2, 2017

  • $ 2500
  • Industry report
  • November 2017
  • by GlobalData

Keratitis Global Clinical Trials Review, H2, 2017SummaryGlobalData’s clinical trial report, “Keratitis Global Clinical Trials Review, H2, 2017" provides an overview of Keratitis clinical trials scenario. ...

Leprosy Global Clinical Trials Review, H2, 2017

Clinical Research in Leprosy in H2, 2017

  • $ 2500
  • Industry report
  • November 2017
  • by GlobalData

Leprosy Global Clinical Trials Review, H2, 2017SummaryGlobalData’s clinical trial report, “Leprosy Global Clinical Trials Review, H2, 2017" provides an overview of Leprosy clinical trials scenario. ...


ref:plp2014

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.